The protective effect of GLP-1 RAs was particularly evident in patients with obesity (aHR: 0.61, 95% CI: 0.50–0.77), whereas no significant benefit was noted in non-obese individuals (aHR: 0.94, 95% CI: 0.67–1.31). The gene discussed is GLP1R; the disease is obesity disorder.